-
Understanding fibrosis Table 1. TGFB1 and Rho kinase inhibitors. Transforming growth factor-b1 (TGFB1) inhibitors Company Product Disease category Indication Development InterMune Inc. (NASDAQ:ITMN) Esbriet …
Published on 3/21/2013
-
Targets & Mechanisms: Placing kinases in the WNT pathway Figure 1. WNT signaling in cancer. A Boston-based team and a Genentech Inc.-led team have each identified a new kinase-v-yes-1 Yamaguchi sarcoma viral oncogene…
Published on 3/14/2013
-
A Boston-based team and a group led by Roche's Genentech unit have each identified new kinase regulators of WNT signaling-YES1 and RIPK4, respectively-that provide two new, druggable targets. Each team will now look for…
Published on 3/14/2013
-
Separate teams from New York University and Columbia University have identified mutations in NT5C2 that predict relapse, drug resistance and poor prognosis in ALL. Inhibiting the enzyme could help sensitize some …
Published on 3/7/2013
-
German and U.S. researchers have shown that intra-adrenal transplantation of islet cells preconditioned with an improved peptide agonist of GHRH may normalize glucose levels in diabetic mice better than existing …
Published on 2/28/2013
-
Researchers at the Penn State Milton S. Hershey Medical Center have identified a small molecule inducer of TRAIL expression that has antitumor effects in multiple mouse models. Oncoceutics has licensed the findings and …
Published on 2/28/2013
-
Harvard Medical School researchers have shown that the plant-derived small molecule huperzine A can reduce neuropathic pain in mice with spinal cord injury. Insero Health has licensed IP covering epilepsy and …
Published on 2/21/2013
-
Two independent teams have identified activating mutations in the promoter of TERT that occur in more than 70% of melanoma cases. The functional role of these mutations still needs further exploration before their …
Published on 2/21/2013
-
Targets & Mechanisms: Stressing out over depression and anxiety Figure 1. Dopamine stressed out over glucocorticoids. Environmental triggers induce the release of plasma glucocorticoids [a], which influence dopamine …
Published on 2/14/2013
-
MIT researchers have shown that the widely used cholesterol drug lovastatin can correct fragile X syndrome in mice. The findings add to a growing list of unconventional strategies for this common form of mental …
Published on 2/14/2013
-
Two teams have shown that enhanced glucocorticoid signaling in the brain triggers aberrant behavior in mouse models of depression and anxiety. The groups are now studying the mechanisms underlying the effect to …
Published on 2/14/2013
-
NIBR and UCSF researchers have shown that altering the dosing regimen of Zelboraf can prevent the development of drug resistance in mouse models of melanoma. The team will now test an intermittent Zelboraf dosing …
Published on 2/7/2013
-
Laval University and GlaxoSmithKline have shown that peripheral administration of the adjuvant MPL can help treat Alzheimer's disease in mice. Although the findings point to a potential immunomodulatory approach for …
Published on 1/31/2013
-
European researchers have shown that NOD2 deficiency can disrupt enteric microbiota and predispose the host to colitis and colitis-associated cancer. The group is seeking to understand how NOD2 deficiency leads to …
Published on 1/24/2013
-
Japanese and U.S. researchers have shown that inhibiting gamma-secretase in the middle ear can promote hair cell regeneration and recovery from deafness in rodents. Keeping potentially toxic gamma-secretase inhibitors …
Published on 1/17/2013
-
A group of U.S. researchers has developed inhibitors of the influenza A virus M2 mutant that is responsible for most resistance to amantadine. InfluMedix has licensed the compounds and expects to bring a new influenza …
Published on 1/17/2013
-
Novartis has shown that the absence of pyruvate kinase M2 isozyme has no effect on cancer cell proliferation in mice, thus suggesting PKM2 inhibition alone might not be an effective strategy to stop tumor growth. …
Published on 1/17/2013
-
Targets & Mechanisms: What to do with PKM2 Figure 1. Metabolic pathways regulated by pyruvate kinase. To block the cancer metabolism pathway driven by the pyruvate kinase M2 isozyme (PKM2) dimer, researchers are …
Published on 1/17/2013
-
German researchers have implicated the inflammasome as a key player in Alzheimer's disease. The findings provide additional evidence that AD could be treated with anti-inflammatory agents that act upstream of Beta-…
Published on 1/10/2013
-
Emory University School of Medicine researchers have identified excessive daytime sleepiness as a repurposing opportunity for flumazenil. A new formulation may allow for the use of GABA A receptor antagonists in this …
Published on 12/20/2012
-
Researchers at Charite-University Hospital Berlin and the University of Zurich have shown that p40, a protein subunit shared by IL-12 and IL-23, could be a new therapeutic target in Alzheimer's disease. The group now …
Published on 12/20/2012
-
Muscling up on Myozyme Figure 1. Next-generation Myozyme. Researchers from Oxyrane U.K. Ltd. and BioMarin Pharmaceutical Inc. have separately published two new strategies for delivering Pompe's disease enzyme …
Published on 12/13/2012
-
Oxyrane and BioMarin have separately reported on their next-generation enzyme replacement therapies for Pompe's disease. Both molecules cleared glycogen from mouse muscle better than the marketed drug Myozyme from …
Published on 12/13/2012
-
Therapeutic strategies for Alzheimer's disease that aim to reduce levels of beta-amyloid have thus far come up empty-handed in the clinic. Now, two European teams have proposed contrasting strategies focused on hitting …
Published on 12/6/2012
-
Thinking outside the amyloid box Figure 1. APP processing in AD. In early Alzheimer's disease pathogenesis, amyloid precursor protein (APP) is processed by a series of proteases to yield several neurotoxic protein …
Published on 12/6/2012